Skip to main content
Premium Trial:

Request an Annual Quote

CyBio, Axxam Collaborate on New Luminescence Screening Assays

NEW YORK, Feb. 9 (GenomeWeb News) - CyBio, a Jena, Germany-based life sciences firm, will use Axxam's microarray technology and automated luminescence screening systems to develop and market new technologies for drug discovery, the companies announced this week.

 

Under the terms of the agreement, Axxam, a drug-discovery firm based in Milan, Italy, will pair its Photina arrays with several CyBio technologies including the CyBi Cellight System, an automated assay platform, and the Lumax flash HT Reader, which enables high-throughput screening, according to the firms.

 

CyBio said that it has already generated new technologies using Axxam's assay technology. Axxam said it is using Photina, a calcium-detecting photoprotein that can be used in high-throughput and ultra-high-throughput screenings, to expand its capabilities as a provider in assays and services in the drug-discovery market.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.